Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Helius Medical Technologies, Inc. (HSDT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.34000.0000 (0.00%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5000
Open1.5100
Bid1.1000 x 800
Ask1.5400 x 1100
Day's Range1.4350 - 1.5100
52 Week Range1.0600 - 17.2600
Volume128,517
Avg. Volume29,819
Market Cap5.156M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-8.1600
Earnings DateMar 08, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • GlobeNewswire

    Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    NEWTOWN, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective May 23, 2022, its independent directors approved equity awards under Helius’ 2021 Inducement Plan, as a material inducement to four individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires

  • GlobeNewswire

    Helius Medical Technologies, Inc. Announces Participation of Dr. Deborah Backus and Shepherd Center in its Therapeutic Experience Program

    -- Second Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis --NEWTOWN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the addition of Shepherd Center in Atlanta, Georgia to its Therapeutic Experien

  • GlobeNewswire

    Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS®

    -- Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing -- NEWTOWN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended March 31, 2022. First Quarter and Recent Business Updates U.S. commercial launch of PoNS® for multiple sclerosis (“MS”) commenced with 23 prescriptions written and 2 filled.Finaliz

Advertisement
Advertisement